Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Shares Outstanding (Diluted Average): 2010-2025

Historic Shares Outstanding (Diluted Average) for Northwest Biotherapeutics (NWBO) over the last 7 years, with Sep 2025 value amounting to $1.5 million.

  • Northwest Biotherapeutics' Shares Outstanding (Diluted Average) rose 18.56% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 18.56%. This contributed to the annual value of $1.2 million for FY2024, which is 10.99% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $1.5 million for Q3 2025, which was up 3.75% from $1.4 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $1.5 million during Q3 2025, with a 5-year trough of $834,605 in Q1 2021.
  • In the last 3 years, Northwest Biotherapeutics' Shares Outstanding (Diluted Average) had a median value of $1.2 million in 2024 and averaged $1.2 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 66.16% in 2021, then declined by 13.38% in 2022.
  • Northwest Biotherapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $1.0 million in 2021, then climbed by 0.79% to $1.0 million in 2022, then grew by 10.17% to $1.1 million in 2023, then increased by 10.99% to $1.2 million in 2024, then increased by 18.56% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.4 million for Q2 2025, and $1.4 million during Q1 2025.